GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingGSK.LSE
Biotech & Genomic Medicine▲
GSK's Jemperli gets FDA priority review for rectal cancer
GSK said the FDA has accepted its supplemental Biologics License Application for Jemperli, also known as dostarlimab, for priority review in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer. The FDA has set a PDUFA action date of February 2027. The application is also eligible for expedited review under the National Priority Voucher program, which could lead to an earlier FDA decision. The application is based on positive data from the registrational phase II, single-arm AZUR-1 trial, which met its primary objective by demonstrating a meaningful and sustained clinical complete response rate for 12 months with no detectable signs of cancer for at least one year.
Trump executive order unlikely to hit vaccine makers, analysts say
Seeking Alpha analysts say President Donald Trump's executive order changing childhood vaccine recommendations is unlikely to materially hurt vaccine makers. Stephen Ayers called the order directionally negative for pediatric vaccine-heavy names but expects it to be challenged and go unimplemented, noting Merck's M-M-R II, ProQuad, and Varivax generated $592 million in Q2 2026. ALLKA Research said Merck and GSK are key players, with GSK's Priorix, Priorix Tetra, and Varilrix generating only $97 million in sales, and that any policy change would likely face litigation from groups such as the American Academy of Pediatrics. Gen Alpha expects little to no impact because the executive order is not law and is unlikely to change public perception.
GSK Reports Q2 Results and Accelerates Pipeline Plans
GSK reported second-quarter financial results on July 28, with total turnover rising 5% at constant exchange rates to £8.4 billion, while core operating profit climbed 7% to £2.80 billion and core EPS rose 9% to 50.5p. Total operating profit dropped 75% to £481 million after a £1.3 billion non-cash impairment charge tied to discontinuing camlipixant following Phase III trial results. Management announced it now expects more than 20 Phase III trial starts in 2026, up from a prior projection of 10, and launched a three-year 'Accelerate Growth' restructuring program aimed at generating £1.9 billion in annual cost savings by 2029 at a total cost of £2.4 billion. ViiV Healthcare, GSK's majority-owned HIV business, presented positive Phase IIIb VOGUE study data supporting its long-acting HIV regimen portfolio.
Experts warn splitting MMR vaccine could take a decade
President Donald Trump's executive order aimed at splitting the combined measles, mumps and rubella vaccine faces a major hurdle because none of the individual disease shots are currently licensed in the U.S. Only Merck and GSK are licensed to make combined MMR shots for U.S. patients, and Merck stopped manufacturing individual vaccines for these diseases nearly two decades ago. Merck said even under current expedited review pathways it could take years, potentially as many as 10, to meet safety and efficacy requirements for FDA approval and begin manufacturing and commercialization of single-disease shots. Andrew Racine, president of the American Academy of Pediatrics, said each constituent would have to be manufactured and tested, and that drugmakers probably could not do that for another 10 years. The American College of Physicians warned the order could increase costs to patients and families and place a greater burden on families needing multiple appointments.
Spero Therapeutics Reports Q2 2026 Loss, FDA Approval of Utebzi
Spero Therapeutics reported a net loss of $9.6 million for the second quarter of 2026, compared to a net loss of $1.7 million in the same period last year, while highlighting the FDA approval of its antibiotic Utebzi. The company recorded no revenue in the quarter, down from $14.2 million a year earlier, as prior collaboration revenue from Pfizer and GSK was fully realized. Research and development expenses fell to $3.4 million from $10.7 million due to reduced clinical activity, while general and administrative expenses rose to $6.5 million from $5.9 million. Spero also announced it closed a $105 million non-dilutive, non-recourse royalty financing with Healthcare Royalty, extending its cash runway into the second half of 2029. The company said the FDA approved Utebzi on June 17, 2026, for complicated urinary tract infections, making it the first oral carbapenem approved in the US, with GSK holding exclusive commercialization rights worldwide excluding certain Asian territories.
GSK Prelet Drives UK Lab Space Demand to Record High
GSK's landmark life sciences prelet has driven UK laboratory space demand to a new record, according to data from CoStar. Rolling four-quarter take-up exceeded 1.2 million square feet in the third quarter of 2026, with two months still remaining, following the 300,000-square-foot prelet at Cambridge Biomedical Campus. Cambridge activity has rebounded in 2026, with year-to-date leasing volumes above 180,000 square feet, nearly double Oxford's total, and the GSK deal brings volumes in the first seven months to almost 500,000 square feet, matching the previous record year in 2015. However, UK laboratory vacancies reached a record 14.3 percent in the second quarter, more than doubling in two years as Golden Triangle levels exceeded 25 percent, following 1.8 million square feet of new lab space delivered over the past two years. Geopolitical risks, economic uncertainty, and rising construction costs are expected to slow development, with less than 130,000 square feet starting on site so far in 2026, one of the lowest levels on record, reducing the UK construction pipeline to around 3 million square feet, down about 13 percent since the start of the year.
GSK to open Cambridge R&D hub and partner with Relation Therapeutics
GSK plans to establish a new global R&D centre on the Cambridge Biomedical Campus in the UK, expected to accommodate more than 1,000 scientists. The company has also agreed a research collaboration with Relation Therapeutics that uses advanced cellular biology models and large-scale data generation. The move places GSK at the heart of one of Europe's leading life sciences hubs and signals a stronger focus on data-driven and AI-supported drug discovery.
Relation and GSK expand collaboration on AI-driven drug discovery
Relation announced an expanded strategic research collaboration with GSK to generate large-scale human cellular perturbation data and deploy them into models, including Relation's cellular biology foundation model MORGAN, to deepen understanding of disease biology and support the discovery of potential new therapeutic targets. Under the agreement, Relation may receive up to $110 million in upfront and success-based milestone payments. The collaboration will create high-quality perturbation datasets capturing how human cells respond to genetic and pharmacological interventions, using integrated automation to generate time-resolved data with multi-omics readouts at significant scale and consistency. The resulting data asset will be used to train foundation models and investigate biological pathways, supporting future research aimed at identifying novel therapeutic opportunities. The effort reflects a shared commitment to advancing drug discovery through innovative human biology, large-scale data generation, and foundation model development.
GSK Reports 5% Sales Growth in Q2 2026, Updates Guidance and Pipeline Plans
GSK reported second-quarter 2026 sales rose 5% to more than GBP8.4 billion, with core operating profit up 7% and core earnings per share up 9%. Specialty Medicines revenue grew 14% and Vaccines grew 8%, while General Medicines declined 9%. The company updated its full-year 2026 sales and operating profit guidance towards the upper half of the range, but lowered its EPS outlook to the lower half due to additional interest costs of around GBP160 million from the Nuvalent acquisition. GSK also announced a new 'Accelerate Growth' program targeting GBP1.9 billion in annual cost savings by 2029, and plans to start over 20 Phase III trials in 2026, more than double initial expectations.
Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?
Moderna is set to report second-quarter 2026 earnings on July 31 before the opening bell, with the Zacks Consensus Estimate pegging sales at $126.7 million and a loss of $1.97 per share. The revenue figure suggests a decline from the year-ago levels, but the bottom line is expected to improve. Over the past 30 days, the Zacks Consensus Estimate for 2026 loss per share has widened from $8.26 to $8.64, while the 2027 loss estimate has risen from $4.29 to $4.33. The biotech has beaten earnings estimates in each of the trailing four quarters, delivering an average surprise of 46.21%, including a 60.93% beat in the last reported quarter. However, the Zacks model does not predict a beat this time, as Moderna has an Earnings ESP of -2.41% and a Zacks Rank of 3. Key factors shaping the upcoming results include product sales from two COVID-19 vaccines, Spikevax and mNexspike, and the RSV vaccine mResvia, with the majority of sales expected from COVID-19 vaccines and minimal sales from mResvia due to stiff competition from GSK's Arexvy and Pfizer's Abrysvo. Investors will also seek updates on the commercialization plans for mCombriax, the first combination vaccine against COVID-19 and influenza, which secured EU approval in April, as well as the timeline for FDA resubmission after the initial filing was voluntarily withdrawn last year. Additionally, the FDA decision on Moderna's standalone flu shot, mRNA-1010, is expected by next week, with optimism building after an FDA advisory committee unanimously backed approval. Another key pipeline candidate is intismeran autogene, a personalized cancer therapy developed in collaboration with Merck, which is being evaluated in three pivotal phase III studies in melanoma and non-small cell lung cancer, along with mid-stage studies for other cancer indications. Year to date, Moderna's shares have surged 89%, significantly outperforming the industry's 2% growth, the sector, and the S&P 500, though the stock trades at a premium valuation of 9.91 times trailing 12-month sales compared to the industry's 2.35. Moderna held approximately $8.1 billion in cash and cash equivalents as of March 31, 2026, which, combined with cost-efficiency initiatives, should support its research, development, and commercialization efforts. While the premium valuation and downward estimate revisions warrant caution, existing investors are advised to maintain their positions given the approaching FDA decision on mRNA-1010, the recent EU approval of mCombriax, and a deep pipeline spanning oncology and other therapeutic areas.
The FTSE 100 rose 0.8% on Tuesday, lifted by strong earnings and a drop in oil prices that offset concerns from a chip-sector sell-off in Asia. The blue-chip index closed up 89.27 points at 10,871.02, while the FTSE 250 added 0.5% and the AIM All-Share fell 0.5%. Unilever and Croda both surged 8.0% after well-received results, and GSK advanced 3.5% on better-than-expected second-quarter profit, but Barclays dropped 4.8% following what analysts called a messy set of numbers. Brent oil fell to 84.87 dollars a barrel from 89.71 dollars, and the pound was little changed at 1.3306 dollars ahead of the Federal Reserve's interest rate decision.
Gilead, GSK, and Pfizer Leaders to Headline Bioprocessing Summit 2026 Plenary on AI in Quality
Leaders from Gilead Sciences, GSK, and Pfizer will headline the opening plenary of the 18th Annual Bioprocessing Summit in Boston this August, exploring how AI and digital technologies are reshaping biopharmaceutical quality. The plenary presentation, delivered by Anthony Mire-Sluis, Senior Vice President of Global Quality at Gilead Sciences, will focus on practical strategies for integrating digital technologies and AI into quality organizations while maintaining scientific rigor and regulatory compliance. A subsequent fireside chat moderated by Susan Hynes, Global Head of Quality at GSK, will feature Mire-Sluis alongside Lynn Bottone, Senior Vice President of Quality Operations, Environment, Health & Safety at Pfizer, discussing regulatory expectations and organizational readiness. The Summit, taking place August 10-13, 2026, will bring together 1,000 scientists, engineers, and technology innovators across 12 conference tracks and more than 300 scientific presentations.
GSK launches £1.9 billion savings drive to fund drug pipeline
GSK has launched a £1.9 billion cost-savings program to help fund late-stage studies and accelerate drug development. The three-year initiative aims to simplify the organization and reallocate capital and resources, CEO Luke Miels said in a statement. The British drugmaker also beat second-quarter profit expectations and announced a £400 million investment in the UK, including a new R&D centre. Shares rose 4.2% by 1120 GMT.
GSK Q2 earnings expected to plunge 97% ahead of CEO strategy event
GSK is expected to report a 97.3% year-over-year decline in earnings per share when it releases second-quarter results on Tuesday before the market opens. The consensus EPS estimate stands at $1.25, while revenue is forecast to rise 37.4% to $10.98 billion. The company’s Specialty Medicines unit, which includes respiratory, immunology and inflammation, oncology, and HIV, is projected to deliver double-digit sales growth across all therapy areas, though generic competition for certain legacy products may pose a headwind. On the same day, CEO Luke Miels will host an “Accelerate Growth” event where he is expected to outline his strategy, with analysts at UBS focusing on whether he can provide a credible path to achieving the sales target of more than £40 billion by 2031 and an update on pipeline reprioritization following the acquisition of Nuvalent.
Food Allergy Market Valued at $2.7 Billion in 2025, Projected to Grow at 9.4% CAGR Through 2036
The food allergy market across the seven major markets was valued at approximately USD 2.7 billion in 2025 and is projected to expand at a robust CAGR of 9.4% through 2036, according to DelveInsight. The seven major markets comprise the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Key approved therapies include peanut allergen powder (PALFORZIA), omalizumab (XOLAIR), and epinephrine nasal spray (NEFFY). The pipeline features several emerging therapies, including DBV Technologies' Viaskin Peanut Patch in Phase III, Novartis' remibrutinib in Phase II, Aravax's PVX108 in Phase II, GSK's ozureprubart in Phase II, and Aquestive Therapeutics' epinephrine sublingual film ANAPHYLM in Phase III. GSK strengthened its position through the acquisition of RAPT Therapeutics, gaining access to ozureprubart.
U.S. measles cases surpass 2025 total to hit 35-year high
The U.S. has recorded 2,318 measles cases this year, exceeding the 2025 total of 2,289 and marking the highest annual count since 1991, according to the Centers for Disease Control and Prevention. As of July 23, 45 jurisdictions reported 2,302 cases, with 16 infections linked to international visitors. While no deaths have occurred this year, 151 hospitalizations were recorded, representing 7% of total cases compared with 11% in 2025. Nearly 93% of cases were in unvaccinated individuals or those with unknown vaccination status, and the CDC emphasized that the MMR vaccine, marketed by Merck and GSK, is the most effective protection. The rise comes as the U.S. risks losing its measles elimination status, achieved in 2020, with the Pan American Health Organization set to evaluate data in November after Canada lost its status last year.
GSK Could Be 10% Undervalued After Jideytro FDA Approval
GSK has received US FDA approval for Jideytro, a ROS1 selective inhibitor for previously treated ROS1 positive non small cell lung cancer, providing a fresh catalyst from its oncology pipeline. Despite the approval, GSK's share price has eased in recent weeks, with a 30-day return of negative 2.66% and a 90-day return of negative 5.67%, though the one-year total shareholder return stands at 42.21% and the five-year return at 65.00%. A widely followed narrative estimates GSK's fair value at £21.14 per share, compared to the last close of £19.06, suggesting the stock is about 9.9% undervalued. The valuation is underpinned by steady revenue expansion, firmer margins, and a rerating in the profit multiple, driven by strong volume growth in high-margin areas such as oncology, immunology, and HIV, as well as robust demand for vaccines and specialty medicines. However, the narrative also highlights risks including Zantac litigation cash outflows and future patent expiries that could undermine earnings assumptions.
Summit Therapeutics Reports $690.7 Million Cash Position and Ivanizumab Progress in Q2 2026
Summit Therapeutics reported a cash position of approximately $690.7 million at the end of the second quarter of 2026, up from the prior quarter. The company's lead investigational asset, Ivanizumab, has generated positive data in four Phase III clinical studies, securing two approvals in China and a pending Biologics License Application with the U.S. FDA. GAAP operating expenses rose to $220.5 million, driven by higher research and development costs. The HARMONY trial showed consistent overall survival benefit across regions, and Summit has initiated over 50 clinical trials for Ivanizumab across a range of solid tumors, while also establishing collaborations with GSK and Arcus Biosciences to explore novel combinations.
GSK's First Lung Cancer Drug Wins Early FDA Approval
British pharmaceutical giant GSK announced that its first lung cancer drug, Jiditro, has received marketing approval from the US Food and Drug Administration. The approval came ahead of the original review deadline, allowing GSK to enter the highly profitable lung cancer treatment market. Jiditro was acquired from the US biopharmaceutical company Newvalent, which GSK bought for 10.6 billion dollars about two months ago. It has been approved for patients with previously treated ROS1-positive non-small cell lung cancer. In early to mid-stage clinical trials, tumors shrank or disappeared in 44 percent of 117 patients, and among those who responded, 82 percent maintained their response at six months and 69 percent at twelve months. With this approval, GSK aims to accelerate the turnaround of its oncology business under new CEO Luke Miles and achieve its target of over 40 billion pounds in revenue by 2031.
Biotech IPOs Surge 55% as AI Listings Lose Momentum
Biotechnology and pharmaceutical IPOs have generated a weighted average return of 55% in the U.S. market this year, sharply outperforming the broader market's 4.4% weighted average loss, according to Bloomberg data through July 17. The strong performance is drawing more drug developers to go public, with at least six filing this month, led by Scribe Therapeutics, and the number of completed biotech IPOs in 2026 already surpassing last year's total while proceeds exceed $5 billion, roughly three times the prior year's amount. Parabilis Medicines raised $770.6 million in the largest biotech IPO on record, and Veradermics has gained more than 500% since its February debut, making it the best-performing U.S. IPO across all sectors. The sector's recovery is supported by a 13% gain in the Nasdaq Biotechnology Index, a stable regulatory environment, and renewed acquisition activity, including three deals valued at $10 billion or more announced in the past month involving AbbVie, GSK, and Vertex Pharmaceuticals. Investment bankers note that major fund groups are reallocating capital toward healthcare, though higher interest rates could pose a headwind.
GSK Drops Chronic Cough Drug Camlipixant After Mixed Trial Results
GSK has stopped developing its experimental chronic cough drug camlipixant after mixed late-stage trial results, sending shares down as much as 4.5 percent. The decision came after a high dose reduced cough frequency in one study but failed to meet the same goal in another trial involving a different patient population. The setback removes one of the company's limited late-stage clinical readouts expected this year and could add pressure to CEO Luke Miels' effort to lift annual sales to 40 billion pounds, or 53.8 billion dollars, by 2031. GSK had previously estimated camlipixant could generate more than 2.5 billion in annual sales, though some analysts projected only about 430 million by 2031. Analysts described the outcome as a credibility hit rather than a major financial setback, with some questioning the company's acquisition strategy after it spent 2 billion dollars to acquire the medicine.
Smart Inhalers Market to Reach $12.1 Billion by 2030
The global smart inhalers market is projected to grow from $5.2 billion in 2024 to $12.1 billion by 2030, a compound annual growth rate of 15.4%, according to a new report from BCC Research. The expansion is driven by poor medication adherence among asthma and COPD patients, with compliance rates often below 50%, leading to preventable hospitalizations and emergency visits. North America holds the largest market share, supported by digital health infrastructure and new CMS Remote Therapeutic Monitoring reimbursement codes. Key players include AstraZeneca, GSK plc, Novartis AG, Boehringer Ingelheim International GmbH, Adherium, and Amiko Digital Health Ltd.
EMA Accepts GSK Filing for Bexsero Single-Dose Booster in Adolescents
GSK announced that the European Medicines Agency has accepted its submission to update the Bexsero label to include a single-dose booster for individuals aged 10 years and older who were previously vaccinated in infancy. The submission is supported by a Phase 3b study showing a single booster dose effectively enhanced immune responses in participants aged 10 to 20 who had received the full infant vaccination series. Bexsero is registered in 61 countries and included in 15 infant immunization programs and 3 adolescent programs across Europe, with approximately 138 million doses distributed globally since 2015. If approved, the booster could strengthen adolescent protection against invasive meningococcal disease, which has a fatality rate of 4 to 20 percent and a second peak in incidence among adolescents and young adults. GSK stock closed Friday at $51.76, down 1.91 percent, and edged up 0.08 percent in afterhours trading to $51.80.
American Kidney Fund adds lupus nephritis course to its Kidney Health Coach program
The American Kidney Fund has launched an online course on lupus nephritis through its Kidney Health Coach program. The course, developed with AKF’s subject matter expert planning committee, covers recognizing signs and symptoms, promoting patient-care team conversations, understanding testing and diagnosis, and navigating treatment options. It expands the curriculum for more than 8,000 volunteer Kidney Health Coaches across all 50 states, who will also receive a community presentation supported by GSK. An estimated 1.5 million Americans have lupus, and about half of adults with the condition develop lupus nephritis, with higher risk among men and racial and ethnic minorities. AKF President and CEO LaVarne A. Burton said the course empowers coaches with foundational knowledge to drive better health outcomes.
Brodsky & Smith Investigates Five Merger Deals for Potential Breach of Fiduciary Duty
Brodsky & Smith is investigating five proposed acquisitions for possible breaches of fiduciary duty by the target companies' boards. The deals under scrutiny include Eli Lilly's purchase of AtaiBeckley for $6.75 per share in cash plus up to $2.50 per share in contingent value rights, LKCM Headwater Investments' acquisition of Distribution Solutions Group for $35.00 per share in cash, Knox Lane's all-cash buyout of Cross Country Healthcare at $13.25 per share in a deal valued at $437 million, GSK's acquisition of Nuvalent for $124.00 per share in cash in a transaction valued at $10.6 billion, and Eaton Corporation's merger with Dana in a deal valued at approximately $5.1 billion where Eaton shareholders will own at least 50.1% and Dana shareholders approximately 49.9% of the combined company. The investigations focus on whether the boards failed to conduct a fair process and whether shareholders are receiving fair value.
European Markets Summary: London Stocks Rebound, Consumer Staples in Demand
The London stock market closed higher, with the FTSE 100 rebounding. Amid a global sell-off in tech stocks, consumer staples were bought, sending the FTSE 350 Personal Goods index up 2.61%, the Beverages index up 2.36%, and the Retail index up 1.92%. Pharmaceutical giant GSK rose 2.1%, while AstraZeneca gained 0.5%. Automation solutions firm Rotork surged 66.8% after Swiss heavy electrical equipment giant ABB announced its acquisition. European equity markets rose for a third straight session, with the STOXX Europe 600 up 0.16%. The Basic Resources index fell 1.38%, while the Media index climbed 1.43%. Dutch firm ASML Holding rose 3.2%, but STMicroelectronics fell 4.9% and BE Semiconductor dropped 3.2%. Norway's Telenor tumbled 11.6% after lowering its full-year outlook. In eurozone bond markets, the German 10-year yield rose 3 basis points to 3.135%, its highest since May 20. The German-US 10-year yield spread narrowed to 143 basis points. In currencies, the euro traded at 1.1446 dollars, and the dollar at 162.42 yen.
Tuberculosis Pipeline Features Over 30 Drugs in Development from 28-Plus Companies
A new report from DelveInsight reveals that more than 28 companies are actively developing over 30 pipeline drugs for tuberculosis. Key players include Biofabri, Otsuka Pharmaceutical, GlaxoSmithKline, Archivel Farma, BioNTech, CanSino Biologics Inc., Medincell, and others, with promising therapies such as MTBVAC, Quabodepistat, GSK3036656, RUTI, BNT164, and Ad5-105K in various clinical stages. Approximately four-plus drugs are in late-stage development, and notable mechanisms of action include leucyl-tRNA synthetase inhibitors, immunostimulants, and DprE1 protein inhibitors. The report also highlights recent milestones, including the first patient dosed in a Phase IIb trial of alpibectir-ethionamide in March 2026 and the initiation of a new cohort in the IMAGINE trial of MTBVAC in February 2026.
Laughing Water Capital Adds AnaptysBio as New Position, Sees Potential 50-80% Upside
Laughing Water Capital added AnaptysBio as a new position in the second quarter of 2026, citing a special situation that could resolve quickly. Following a taxable spinoff of its developmental drug assets, AnaptysBio is now an asset-light royalty company collecting payments on sales of Jemperli, a cancer drug commercialized by GSK. The firm believes it purchased shares at a discount to the present value of future royalties, but sees additional upside from a trial set for July 14-17 in which AnaptysBio accuses GSK of violating their commercial agreement. If AnaptysBio prevails, it could recover the entirety of Jemperli, potentially pushing shares to nearly $300 versus an average purchase price below $60. A more likely scenario, according to Laughing Water Capital, is a settlement or outright acquisition by GSK, which could yield 50 to over 80 percent upside.
Global Vaccine Sales Market to Reach US$141.40 Billion by 2036
The global vaccine sales market is projected to grow from US$76.40 billion in 2026 to US$141.40 billion by 2036, expanding at a compound annual growth rate of 6.3%. Growth is supported by rising infectious disease prevalence, broader government-funded immunisation programmes in low- and middle-income countries, and sustained investment in mRNA, viral vector, DNA and needle-free vaccine technologies. Platform-based technologies are enabling developers to pursue multiple disease targets, with programmes such as Moderna and Merck's mRNA-4157 illustrating the expanding role of mRNA in oncology. In December 2025, the Coalition for Epidemic Preparedness Innovations committed up to US$54.3 million to support a Phase III trial of Moderna's mRNA-based H5 pandemic influenza vaccine candidate, advancing the first mRNA influenza vaccine into pivotal-stage development. The market remains sensitive to U.S. tariff policies and supply-chain pressures, prompting companies to localise manufacturing and diversify suppliers. Key players include GSK, Pfizer, Sanofi, Moderna, Merck, BioNTech, AstraZeneca and Serum Institute of India, with the report profiling 21 companies in total.
GSK's Jemperli achieves sustained complete clinical response in phase 2 rectal cancer trial
GSK announced that interim results from the phase 2 AZER-1 trial showed patients with a certain type of rectal cancer given Jemperli, also known as dostarlimab, achieved a sustained complete clinical response rate at one year. The enrolled patients had stage II/III mismatch repair deficient/microsatellite instability-high locally advanced rectal cancer, which represents about 5% to 10% of this type of cancer. GSK noted that if approved, Jemperli would become the first immunotherapy that could eliminate or delay the use of chemotherapy, radiation, and surgery for this group of rectal cancer patients.
Hansoh Pharma's Ris-Rez shows survival benefit in lung cancer trial
Hansoh Pharmaceutical Group announced positive Phase III results for its investigational therapy Ris-Rez in small-cell lung cancer. The ARTEMIS-008 trial met its primary endpoint, demonstrating statistically significant and clinically meaningful overall survival improvement versus topotecan. Consistent benefits were also seen in secondary endpoints including progression-free survival, with a safety profile consistent with earlier studies and no new safety signals. These are the first pivotal Phase III overall survival data for a B7-H3-targeted antibody-drug conjugate in any tumor type. GSK holds exclusive global rights to Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan, and is advancing a broad clinical program with pivotal global Phase III data expected next year.
Ionis extends losses as Roche scraps two partnered studies
Ionis Pharmaceuticals shares extended losses after Roche discontinued two clinical studies for partnered Huntington’s disease therapies. Roche halted a Phase 2 trial of tominersen in early Huntington’s disease after it missed its efficacy goal, and will also discontinue the Phase 1 POINT-HD study of RG6496 because animal testing showed it cannot be given chronically with repeated doses. Neither decision was related to safety events in trial participants. Ionis fell about 8% in morning trading, adding to a more than 20% drop on Thursday after a late-stage trial setback for a GSK-partnered therapy. Despite the setbacks, Ionis reaffirmed its full-year financial guidance, including projected 2026 revenue of $875 million to $900 million.
COPD Market to Reach USD 40.39 Billion by 2035, Growing at 4.89% CAGR
The global chronic obstructive pulmonary disease market is projected to grow from USD 25.06 billion in 2025 to USD 40.39 billion by 2035, at a compound annual growth rate of 4.89 percent, according to a new report by SNS Insider. Bronchodilators held the largest revenue share in 2025 at 48.10 percent, while corticosteroids are expected to register the fastest CAGR of 5.04 percent through 2035. Chronic bronchitis accounted for 60.80 percent of market revenue in 2025, and the treatment segment captured 65.10 percent of revenue. North America led with over 38.40 percent market share in 2025, while Asia Pacific is forecast to grow at the highest CAGR of 5.99 percent. Key players include AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Pharmaceutical Industries.
Alector stock plummets 13% as GSK terminates neuroscience pact
Alector shares dropped 13% in extended trading after GSK terminated their neuroscience collaboration covering two experimental antibody drugs following clinical setbacks. The decision comes after a late-stage study of latozinemab failed last year and a mid-stage Alzheimer's trial of nivisnebart was discontinued in April. The termination will be effective January 2, 2027. Under the 2021 deal, Alector received $700 million upfront from GSK and could have earned up to $1.5 billion in milestone payments and royalties.
The FTSE 100 closed down 0.3% on Monday, pressured by declines in gold miners and AstraZeneca alongside soft UK construction data. The UK construction PMI edged up to 38.4 in June from 38.2 in May, remaining deep in contraction territory. AstraZeneca fell 2.5% and GSK dropped 1.6%, while Fresnillo and Endeavour Mining lost 2.4% and 2.5% respectively as gold prices weakened. On the FTSE 250, easyJet surged 9.3% after reaching an agreement in principle for a takeover by Castlelake at 690 pence per share, valuing the airline at over £5 billion. ITV slipped 0.1% after announcing it will return £950 million to shareholders from the sale of its Media & Entertainment business to Sky for up to £1.6 billion.
GSK Launches Tender Offer to Acquire Nuvalent for $124 Per Share
GSK announced that its indirect wholly owned subsidiary, Harmony Row Acquisition Co., has formally launched a tender offer to acquire all outstanding Class A and Class B common shares of Nuvalent for $124.00 per share in cash. The offer is being made pursuant to the previously announced merger agreement signed on June 9, 2026, and represents the next step toward completing the planned acquisition. The tender offer is subject to applicable withholding taxes and the conditions outlined in the offer documents.
GSK Wins FDA Approval for Utebzi and Orphan Drug Designation for Momelotinib
GSK and Spero Therapeutics received U.S. FDA approval for Utebzi, a first-in-class oral carbapenem antibiotic for complicated urinary tract infections, while GSK's momelotinib gained Orphan Drug Designation for VEXAS syndrome. Utebzi offers an oral treatment option for multidrug-resistant infections, addressing a market with over 3 million U.S. cases annually and high treatment failure rates. The Orphan Drug Designation for momelotinib adds a rare disease asset to GSK's portfolio, potentially providing regulatory support and market exclusivity. These milestones highlight GSK's focus on specialty medicines and infectious diseases, though financial impact will depend on clinical adoption and commercialization.
Global HPV Vaccines Market Projected to Reach $18.4 Billion by 2034
The global HPV vaccines market is projected to grow from $8.9 billion in 2025 to $18.4 billion by 2034, at a compound annual growth rate of approximately 8%, according to a report by DelveInsight. North America held the largest share in 2025, contributing about 41% of total market revenue, driven by strong awareness, CDC recommendations, and widespread use of advanced vaccines like Gardasil 9. Key companies in the market include GlaxoSmithKline, Xiamen Innovax, Walvax Biotechnology, Merck & Co., and Serum Institute of India. Growth is fueled by rising HPV-related cancer prevalence, expanding national immunization programs, the WHO’s cervical cancer elimination strategy, and the introduction of nonavalent vaccines offering broader protection. Recent developments include Merck presenting long-term effectiveness data for GARDASIL 9 and GARDASIL at the EUROGIN 2026 congress, and China’s NMPA approving Cecolin 9, the first HPV 9-valent vaccine from a developing country.
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
The U.S. Food and Drug Administration has approved Utebzi, the first oral carbapenem antibiotic for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options. GSK plc and Spero Therapeutics, Inc. announced the approval on Wednesday, noting that complicated UTIs affect more than 3 million people annually in the U.S., with treatment failure occurring in as many as 34% of patients and multidrug-resistant infections contributing over $6 billion in annual healthcare costs. The decision was supported by Phase 3 PIVOT-PO trial data showing tebipenem pivoxil was non-inferior to intravenous imipenem-cilastatin, with overall success rates of 58.5% versus 60.2% and an adjusted treatment difference of minus 1.3%. GSK expects Utebzi to be available to patients in the U.S. by the end of 2026, and the development received partial federal funding from the Biomedical Advanced Research and Development Authority.
Biopharma industry confidence hits four-year high despite geopolitical headwinds
Biopharma executives' confidence in the industry has reached its highest point in four years, with 55% of surveyed professionals feeling optimistic or very optimistic about growth over the next 12 months, up from 46% in 2023, according to GlobalData's State of the Biopharmaceutical Industry 2026 mid-year update. The survey of 157 pharmaceutical professionals found that 69% of respondents highlighted US tariffs and government actions as the biggest policy concern, a figure that rose to 78% among European respondents. Deal activity has surged, with first-quarter 2026 M&A deal value rising 71% year over year and life sciences and pharma deals surpassing $65 billion, the strongest quarter since 2020. Notable transactions include Eli Lilly's acquisition of 10 companies this year, led by a $7.8 billion deal for Centessa, while the second quarter saw Sun Pharma's $11.75 billion takeover of Organon and GSK's $10.6 billion acquisition of Nuvalent. The IPO market has also resurged, with activity up 210%, and Parabilis Medicines set a new biotech IPO record with a $670 million Nasdaq listing just two months after Kailera Therapeutics raised $625 million.